BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32552577)

  • 1. Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring.
    Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
    Prog Transplant; 2020 Sep; 30(3):249-253. PubMed ID: 32552577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.
    Asempa TE; Rebellato LM; Hudson S; Briley K; Maldonado AQ
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29161757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
    Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
    Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype.
    Friebus-Kardash J; Nela E; Möhlendick B; Kribben A; Siffert W; Heinemann FM; Eisenberger U
    Transplantation; 2022 May; 106(5):1031-1042. PubMed ID: 34241984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
    Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
    Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
    Hesselink DA; van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Zeier M; Budde K; Kuypers DR; Pisarski P; Le Meur Y; Mamelok RD; van Gelder T
    Pharmacogenet Genomics; 2008 Apr; 18(4):339-48. PubMed ID: 18334918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
    Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
    Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
    Tang HL; Xie HG; Yao Y; Hu YF
    Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
    Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
    Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.
    Alvarez-Elías AC; García-Roca P; Velásquez-Jones L; Valverde S; Varela-Fascinetto G; Medeiros M
    Transplant Proc; 2016 Mar; 48(2):631-4. PubMed ID: 27110018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
    Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
    Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression.
    Pasari AS; Balwani MR; Gurjar P; Bawankule C; Bhawane A; Tolani P; Kashiv P; Dubey S; Katekhaye VM
    Transplant Proc; 2023 Jun; 55(5):1305-1309. PubMed ID: 36973144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
    Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
    Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
    Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
    Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients.
    Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
    Transplant Proc; 2019; 51(6):1754-1757. PubMed ID: 31255354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients.
    Komine N; Satoh S; Saito M; Numakura K; Inoue T; Tsuruta H; Narita S; Komatsuda A; Nanjo H; Kagaya H; Niioka T; Miura M; Mitobe Y; Habuchi T
    Int Immunopharmacol; 2018 May; 58():57-63. PubMed ID: 29550576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
    Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
    Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.
    Khan AR; Raza A; Firasat S; Abid A
    Pharmacogenomics J; 2020 Aug; 20(4):553-562. PubMed ID: 31902947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.